Skip to main content
Clinical Trials/NCT03387956
NCT03387956
Completed
Not Applicable

Intravenous Dexamethasone Combined With Intrathecal Atropine to Prevent Morphine-related Nausea and Vomiting After Cesarean Delivery: A Randomized Double-blinded Study

Assiut University1 site in 1 country120 target enrollmentMarch 20, 2017

Overview

Phase
Not Applicable
Intervention
Intrathecal atropine
Conditions
Postoperative Nausea
Sponsor
Assiut University
Enrollment
120
Locations
1
Primary Endpoint
postoperative nausea
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

optimal postoperative pain control with intrathecal morphine, with proper prevention of postoperative nausea and vomiting. Dexamethasone, and or atropine could offer some protection against nausea and vomiting.

Detailed Description

One of the gold standards for analgesia following cesarean delivery is intrathecal morphine, which is not devoid of complications namely postoperative nausea and vomiting. We evaluated the antiemetic effect of intravenous dexamethasone combined with intrathecal atropine after cesarean delivery under spinal bupivacaine plus morphine anesthesia.

Registry
clinicaltrials.gov
Start Date
March 20, 2017
End Date
August 10, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Emad Zarief , MD

Dr

Assiut University

Eligibility Criteria

Inclusion Criteria

  • 18-40 years of age
  • elective cesarean delivery under bupivacaine spinal anesthesia

Exclusion Criteria

  • renal disease
  • preeclampsia
  • liver disease
  • cardiac disease
  • Coagulopathy
  • chronic cough
  • patient refusal

Arms & Interventions

Atropine group

Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.

Intervention: Intrathecal atropine

Dexamethasone group

Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).

Intervention: dexamethasone

Dexamethasone and Atropine group

Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.

Intervention: Intrathecal atropine

Dexamethasone and Atropine group

Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.

Intervention: dexamethasone

Outcomes

Primary Outcomes

postoperative nausea

Time Frame: 24 hours

Monitoring scale of nausea and vomiting

Study Sites (1)

Loading locations...

Similar Trials